Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...
China’s Health Authorities Release Third List of 41 Drugs for Recommended Generic Development
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...
GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment
Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...
CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...
Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study
Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns
Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...
Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO
Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for...
Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...
Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial
China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight...
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...
Junshi Biosciences’ PD-1 Inhibitor Loqtorzi Approved by FDA for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the US...